Q-omics provides the consensus-scored HNRNPA3P10 profile across patient tissues and cancer cell-line models. HNRNPA3P10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA3P10 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, HNRNPA3P10 RNA expression shows 16,605 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, and UVM as cancer lineages where HNRNPA3P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA3P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA3P10 survival associations across molecular data types. HNRNPA3P10 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA3P10 RNA expression–survival associations across cancer types. High HNRNPA3P10 expression shows unfavorable associations in LIHC, ACC, PAAD and KIRP, but favorable associations in LUSC and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HNRNPA3P10 RNA expression.
This table summarizes HNRNPA3P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA3P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA3P10 shows higher tumor expression in LIHC, COAD, UCEC, LUSC, STAD and LUAD. The LIHC box plot shows higher HNRNPA3P10 RNA expression in tumor versus normal tissue (log2 FC = +0.180, t-test p < 0.001).
This table shows molecular features associated with HNRNPA3P10 in patient tissues and cancer cell lines. In patient samples, HNRNPA3P10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
